

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
December 15, 1998

ACCESS PHARMACEUTICALS, INC.

-----  
(Exact name of registrant as specified in its charter)

DELAWARE

-----  
(State of other jurisdiction of incorporation)

0-9314

83-0221517

-----  
(Commission File Number)

-----  
(IRS Employer Identification No.)

2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207

-----  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:

-----  
(214) 905-5100

N/A

-----  
(Former Name or Former Address, if Changed Since Last Report)

Item 4. Changes in Registrant's Certifying Accountants

Effective December 15, 1998, Access Pharmaceuticals, Inc. engaged Grant Thornton LLP as its principal accountants. During the last two fiscal years and the subsequent interim period to the date hereof, the Company did not consult Grant Thornton LLP regarding any of the matters or events set forth in Item 304 (a) (2) (i) and (ii) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ACCESS PHARMACEUTICALS, INC.

By: /s/ Kerry P. Gray

-----  
Title: President and CEO

Dated: December 18, 1998

